Skip to content
Clinical Trials – home

Olopatadine Hydrochloride: A Comprehensive Guide for Patients

1 / 1
trials open to patients / all trials
7+
Countries

In short

This article discusses clinical trials investigating the use of Olopatadine Hydrochloride, an antihistamine medication, in treating allergic conjunctivitis. These studies aim to evaluate the efficacy, safety, and various formulations of Olopatadine Hydrochloride compared to other treatments or placebos. The trials explore different dosages, application methods, and patient populations to determine the most effective use of this drug for managing eye allergy symptoms.

At a glance

Primary Condition Studied
Allergic Conjunctivitis
Main Drug
Olopatadine Hydrochloride
Common Formulations
0.1% and 0.2% ophthalmic solutions
Typical Administration
Eye drops, once or twice daily
Key Outcome Measures
Ocular itching, redness, tearing
Study Designs
Randomized, double-blind, placebo-controlled
Comparators
Placebo (vehicle), other antihistamines
Novel Approaches
Punctal plug delivery system
Patient Populations
Adults, specific ethnic groups (e.g., Chinese, Japanese)
Duration of Treatment
Varies, typically 2-6 weeks

What is Olopatadine Hydrochloride?

Olopatadine Hydrochloride is a medication primarily used to treat eye allergies. It belongs to a class of drugs known as antihistamines, which work by blocking the effects of histamine, a substance in the body that causes allergic symptoms. This medication is available as an ophthalmic solution, which means it's applied directly to the eyes in the form of eye drops.

Olopatadine Hydrochloride is known by several brand names, including:

  • Pataday (0.2% concentration)
  • Patanol (0.1% concentration)

What Conditions Does Olopatadine Hydrochloride Treat?

Olopatadine Hydrochloride is primarily used to treat the following conditions:

  • Allergic Conjunctivitis: This is an inflammation of the conjunctiva (the tissue that lines the inside of the eyelid) caused by an allergic reaction. Symptoms include red, itchy, and watery eyes.
  • Seasonal Allergic Conjunctivitis: This is a type of allergic conjunctivitis that occurs during specific seasons, often due to pollen from trees, grasses, or weeds.
  • Allergic Rhinoconjunctivitis: This condition involves both allergic conjunctivitis and rhinitis (inflammation of the nasal passages), causing symptoms in both the eyes and nose.

How Does Olopatadine Hydrochloride Work?

Olopatadine Hydrochloride works in two main ways:

  1. Antihistamine Effect: It blocks histamine receptors in the eye, preventing histamine from causing allergy symptoms like itching and redness.
  2. Mast Cell Stabilization: It also helps stabilize mast cells, which are cells that release histamine and other substances that cause allergic reactions. By stabilizing these cells, it helps prevent the release of these allergy-causing substances.

Available Formulations

Olopatadine Hydrochloride is available in different concentrations:

  • 0.1% Solution: This is typically used twice daily.
  • 0.2% Solution: This higher concentration is usually used once daily.
  • Preservative-Free Formulation: Some studies have investigated a preservative-free version of Olopatadine, which may be gentler on the eyes for some patients.

Dosage and Administration

The dosage of Olopatadine Hydrochloride depends on the concentration of the solution:

  • 0.1% Solution: Typically, one drop is instilled in each affected eye twice daily.
  • 0.2% Solution: Usually, one drop is instilled in each affected eye once daily.

It's important to follow your doctor's instructions or the directions on the label. Do not use more or less of the medication than prescribed.

Efficacy of Olopatadine Hydrochloride

Clinical trials have shown that Olopatadine Hydrochloride is effective in treating allergic conjunctivitis symptoms. Key findings include:

  • Reduction in ocular itching and redness.
  • Improvement in other symptoms such as tearing and foreign body sensation.
  • Once-daily dosing of the 0.2% solution was found to be as effective as twice-daily dosing of the 0.1% solution.

Potential Side Effects

While Olopatadine Hydrochloride is generally well-tolerated, some patients may experience side effects. Common side effects may include:

  • Mild eye discomfort or irritation
  • Dry eyes
  • Blurred vision
  • Headache
  • Unusual taste in the mouth

If you experience severe or persistent side effects, contact your healthcare provider.

Comparisons with Other Medications

Several studies have compared Olopatadine Hydrochloride to other allergy medications:

  • Olopatadine has been compared to Bepotastine besilate, another antihistamine eye drop. Both medications showed efficacy in treating allergic conjunctivitis symptoms.
  • Some studies have investigated the use of Olopatadine in combination with other treatments, such as nasal sprays, for more comprehensive allergy relief.

Special Considerations

When using Olopatadine Hydrochloride, keep in mind:

  • Contact Lenses: If you wear contact lenses, remove them before applying the eye drops and wait at least 10 minutes before reinserting them.
  • Pregnancy and Breastfeeding: Consult your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
  • Other Medications: Inform your doctor about all medications you are taking, including over-the-counter drugs and supplements.
  • Proper Application: To avoid contamination, do not touch the dropper tip to any surface, including your eyes.

Remember, while Olopatadine Hydrochloride can effectively manage eye allergy symptoms, it's important to work with your healthcare provider to determine the best treatment plan for your specific needs.

Questions people often ask

Conditions where Olopatadine Hydrochloride is being studied

Each condition opens its own overview and trial list

Trials with Olopatadine Hydrochloride

Recruiting trials first

See all 1 →
Quick filters
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).